Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
ReShape Lifesciences Inc. (NASDAQ:RSLS), a micro-cap company currently valued at $6.11 million, has increased its stockholders’ equity above the $2.5 million minimum required for continued listing on The Nasdaq Capital Market, according to an SEC filing released Wednesday. InvestingPro analysis indicates the stock is currently trading below its Fair Value.
The company, which had reported stockholders’ equity of only $1.2 million as of March 31, 2025, raised approximately $6.28 million through two recent stock offerings. Between June 3-6, ReShape sold 593,000 shares in an "at-the-market" offering for gross proceeds of $3.64 million, followed by an additional offering of 1,054,604 shares on June 9 that generated $2.64 million. The stock has shown significant volatility, with InvestingPro data showing an 11.79% return over the last week despite a 97.7% decline year-to-date. InvestingPro subscribers have access to 12 additional key insights about RSLS.
These capital raises come after ReShape received a delisting notice from Nasdaq on May 28 due to non-compliance with the minimum stockholders’ equity requirement. Despite now exceeding the threshold, the company noted that this does not guarantee its securities will avoid delisting.
ReShape has requested a hearing before a Nasdaq Hearings Panel, which has stayed any suspension or delisting action pending the panel’s decision. The company will remain listed during this appeal process and any additional extension period granted by the panel.
The information was disclosed in an 8-K filing with the Securities and Exchange Commission.
In other recent news, ReShape Lifesciences announced the pricing of its public stock offering, with 1,054,604 shares available at $2.50 each, aiming to raise approximately $2.63 million before fees and expenses. This offering is part of an ongoing at-the-market public offering, which initially aimed to raise $9.7 million. Additionally, ReShape Lifesciences has achieved certification for its Quality Management System and medical device portfolio under the EU Medical (TASE:BLWV) Device Regulation and UK Conformity Assessment, allowing continued sales in Europe and the UK. The company has also entered into an exclusive U.S. distribution agreement with Recon Supply to distribute its medical devices across Veterans Administration and Department of Defense healthcare systems. Furthermore, ReShape Lifesciences is progressing with its merger with Vyome Therapeutics, pending Nasdaq’s approval for a new listing application for the combined entity. The merger is expected to enhance the product pipeline and capabilities of the combined company. Investors are encouraged to review the financial statements and management’s discussion provided in the recent 8-K filing for further details. These developments reflect ReShape Lifesciences’ strategic efforts to expand its market presence and financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.